In a report released today, Emily Field from Barclays maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...

A revival in AstraZeneca Plc shares faces a key test this week, with more likely to hinge on the drugmaker’s ability to ...

AstraZeneca scrapped plans for a £450 million UK vaccine plant after rejecting a £78 million government offer, citing ...

In a report released today, James Gordon from J.P. Morgan maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.

Avitas Wealth Management LLC lessened its holdings in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 39.2% in the ...

Britain on Monday hit back at AstraZeneca over the collapse of a 450 million pound ($558.5 million) investment, saying the drugmaker had scaled back the research and development portion of its plans, ...

PHARMACEUTICAL giant AstraZeneca has scrapped plans for a £450m (US$559m) upgrade to its vaccine manufacturing facility in ...

AstraZeneca on Friday scrapped plans to invest 450 million pounds ($558.3 million) in its vaccine manufacturing plant in ...

JPMorgan Chase & Co. reissued an “overweight” rating and issued a £140 ($174.30) price target on shares of AstraZeneca in a report on Friday, November 22nd. Shore Capital reaffirmed a “buy ...

AstraZeneca is asking a court to immediately stop generic drugmakers from their plans to make and sell generic forms of ...